Origin Bio
Cancer-therapeutics data and AI company that profiles real patient tumour tissue to build spatial gene-expression, imaging and clinical datasets, trains models on them to predict drug response, and publishes Axis, a model that generates regulatory DNA elements and predicts their function.
Product
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Origin Bio data engine and Axis Data service
Tumour data engine and models for cancer drug development: tumour blocks from hospital and biobank partners are profiled with matched spatial transcriptomics, H&E imaging and clinical data, models are trained on that data to predict drug response and identify biomarkers, and Axis generates regulatory DNA elements and predicts their function; access is by request through a form on the home page and no prices are published.
Similar products 12
No sourced competitor yet: no filing, vendor document or measured-market report read so far names a rival for this company, so none is asserted. The companies below are the closest by what their products do.
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Total funding
-
Pages read for this record state no funding total. Tried the home page and the company's YC profile.
- Valuation
-
Pages read for this record state no valuation. Tried the home page and the company's YC profile.
- Founded
-
Company disclosure · 20 Oct 2026
Own YC profile lists Founded: 2025; origin.bio states no founding year.
- Public listing
-
No listing on the pages read; treated as private.
- Description
-
Official documentation · 20 Oct 2026
Home page: "Introducing Axis The first AI model that generates regulatory DNA elements and predicts their function." The footer reads "© 2026 Origin Bio"; the page names no legal entity.
Open Origin Bio in the directory
Something wrong here? Send a correction — quote this company id: origin-bio.